[Pharm-policy] US Market for 2 clases of HIV drugs

[James Love]

Thanks to Rachel for this info.  Do these numbers look right?

Source: Mirasol, Feliza, "New Drug Classes Drive Expanding HIV Market,"
Chemical Market Reporter, April 17, 2000 (9,18):

Leading HIV Antivirals
US Market in millions of dollars

Reverse Transcriptase Inhibitors
12 mos. ending Feb/00

Combivir           $ 478.4
Zerit   [d4T]      $ 315.9
Epivir             $ 260.2
Sustiva            $ 178.6
Viramune           $ 108.1
Ziagen [Abacavir]  $ 107.5
Videx   [ddI]      $  78.6
Retrovir           $  55.0
Hivid   [ddC]      $   9.7
Rescriptor         $   7.4
Retrovir IV        $   0.7

Total              $1,600.1

Protease Inhibitors
12 mos. ending Feb/00

Viracept               $  440
Crixivan               $  234
Norvir  [Ritonavir]    $  101
Fortovase              $   80
Agenerase              $   48
Invirase               $   30

Total                  $  933

All figures are rounded
Source: IMS Health and CMR estimates



=======================================================
James Love, Director           | http://www.cptech.org
Consumer Project on Technology | mailto:love@cptech.org 
P.O. Box 19367                 | voice: 1.202.387.8030
Washington, DC 20036           | fax:   1.202.234.5176
=======================================================